Can a shorter chemo regimen work just as well for some lymphoma patients?
NCT ID NCT05018520
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether 4 cycles of R-CHOP followed by 4 cycles of rituximab is as safe and effective as the standard 6 cycles of R-CHOP plus 2 cycles of rituximab for people with newly diagnosed, low-risk diffuse large B-cell lymphoma. The study plans to enroll 640 participants who have already responded well to 4 cycles of R-CHOP. The main goal is to see if the shorter chemo schedule can reduce side effects without increasing the risk of the cancer coming back within two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and rituximab
- What this could lead to
- If successful, this could show that a shorter initial chemo regimen with extra rituximab is just as effective, reducing side effects for low-risk patients.
- What could go wrong
- This is a phase 3 trial, but it only includes low-risk patients who already responded to 4 cycles, so results may not apply to others. There is still a risk of relapse or side effects from the drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, 200020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?